Tokyo Tape
Sign in
← Taiko Pharmaceutical

Annual report

4574.TEDINET S100QI1S
Period2022-01-01 → 2022-12-31
Filed2023-03-30
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 152
MetricValuePeriodScopeSource row
Revenue¥5.0bn2022-01-01 → 2022-12-31Cons.Net sales
Revenue¥11.3bn2021-01-01 → 2021-12-31Cons.Net sales
Revenue¥17.6bn2020-01-01 → 2020-12-31dCons.Net sales (5-year summary)
Revenue¥15.0bn2019-01-01 → 2019-12-31dCons.Net sales (5-year summary)
Revenue¥10.4bn2018-01-01 → 2018-12-31dCons.Net sales (5-year summary)
Operating income−¥3.1bn2022-01-01 → 2022-12-31Cons.Operating income
Operating income−¥4.9bn2021-01-01 → 2021-12-31Cons.Operating income
Ordinary income−¥3.4bn2022-01-01 → 2022-12-31Cons.Ordinary income
Ordinary income−¥6.1bn2021-01-01 → 2021-12-31Cons.Ordinary income
Ordinary income¥5.5bn2020-01-01 → 2020-12-31dCons.Ordinary income loss (5-year summary)
Ordinary income¥3.6bn2019-01-01 → 2019-12-31dCons.Ordinary income loss (5-year summary)
Ordinary income¥1.9bn2018-01-01 → 2018-12-31dCons.Ordinary income loss (5-year summary)
Profit before tax−¥4.9bn2022-01-01 → 2022-12-31Cons.Income before income taxes
Profit before tax−¥8.9bn2021-01-01 → 2021-12-31Cons.Income before income taxes
Net income (owners)−¥4.9bn2022-01-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)−¥9.6bn2021-01-01 → 2021-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥3.9bn2020-01-01 → 2020-12-31dCons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥2.5bn2019-01-01 → 2019-12-31dCons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥1.4bn2018-01-01 → 2018-12-31dCons.Profit loss attributable to owners of parent (5-year summary)
Net income−¥4.9bn2022-01-01 → 2022-12-31Cons.Profit loss
Net income−¥9.6bn2021-01-01 → 2021-12-31Cons.Profit loss
Total assets¥15.0bnat 2022-12-31Cons.Assets
Total assets¥22.5bnat 2021-12-31Cons.Assets
Total assets¥31.8bnat 2020-12-31dCons.Total assets (5-year summary)
Total assets¥25.5bnat 2019-12-31dCons.Total assets (5-year summary)
Total assets¥21.6bnat 2018-12-31dCons.Total assets (5-year summary)
Total liabilities¥7.0bnat 2022-12-31Cons.Liabilities
Total liabilities¥9.7bnat 2021-12-31Cons.Liabilities
Net assets / equity¥8.0bnat 2022-12-31Cons.Net assets
Net assets / equity¥12.8bnat 2021-12-31Cons.Net assets
Net assets / equity¥22.8bnat 2020-12-31dCons.Net assets
Net assets / equity¥19.4bnat 2019-12-31dCons.Net assets (5-year summary)
Net assets / equity¥17.5bnat 2018-12-31dCons.Net assets (5-year summary)
Cash and deposits¥3.1bnat 2022-12-31Cons.Cash and deposits
Cash and deposits¥5.8bnat 2021-12-31Cons.Cash and deposits
Cash & equivalents¥2.8bnat 2022-12-31Cons.Cash and cash equivalents
Cash & equivalents¥5.5bnat 2021-12-31Cons.Cash and cash equivalents
Cash & equivalents¥4.7bnat 2020-12-31dCons.Cash and cash equivalents
Cash & equivalents¥9.6bnat 2019-12-31dCons.Cash and cash equivalents (5-year summary)
Cash & equivalents¥7.2bnat 2018-12-31dCons.Cash and cash equivalents (5-year summary)
Operating cash flow−¥2.0bn2022-01-01 → 2022-12-31Cons.Net cash provided by used in operating activities
Operating cash flow−¥1.6bn2021-01-01 → 2021-12-31Cons.Net cash provided by used in operating activities
Operating cash flow−¥1.5bn2020-01-01 → 2020-12-31dCons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥3.5bn2019-01-01 → 2019-12-31dCons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥1.7bn2018-01-01 → 2018-12-31dCons.Net cash provided by used in operating activities (5-year summary)
Investing cash flow¥190m2022-01-01 → 2022-12-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥1.6bn2021-01-01 → 2021-12-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥2.8bn2020-01-01 → 2020-12-31dCons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥448m2019-01-01 → 2019-12-31dCons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥746m2018-01-01 → 2018-12-31dCons.Net cash provided by used in investing activities (5-year summary)
Financing cash flow−¥997m2022-01-01 → 2022-12-31Cons.Net cash provided by used in financing activities
Financing cash flow¥4.0bn2021-01-01 → 2021-12-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥649m2020-01-01 → 2020-12-31dCons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥581m2019-01-01 → 2019-12-31dCons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥338m2018-01-01 → 2018-12-31dCons.Net cash provided by used in financing activities (5-year summary)
EPS (basic)¥-112.262022-01-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-220.522021-01-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥89.182020-01-01 → 2020-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥57.572019-01-01 → 2019-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥332018-01-01 → 2018-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥88.822020-01-01 → 2020-12-31dCons.Diluted earnings per share (5-year summary)
EPS (diluted)¥57.342019-01-01 → 2019-12-31dCons.Diluted earnings per share (5-year summary)
EPS (diluted)¥32.962018-01-01 → 2018-12-31dCons.Diluted earnings per share (5-year summary)
Net assets per share¥184.6at 2022-12-31Cons.Net assets per share (5-year summary)
Net assets per share¥293.88at 2021-12-31Cons.Net assets per share (5-year summary)
Net assets per share¥525.83at 2020-12-31dCons.Net assets per share (5-year summary)
Net assets per share¥450.94at 2019-12-31dCons.Net assets per share (5-year summary)
Net assets per share¥405.41at 2018-12-31dCons.Net assets per share (5-year summary)
Equity ratio53.5%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio56.8%at 2021-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio71.7%at 2020-12-31dCons.Equity to asset ratio (5-year summary)
Equity ratio76.0%at 2019-12-31dCons.Equity to asset ratio (5-year summary)
Equity ratio80.8%at 2018-12-31dCons.Equity to asset ratio (5-year summary)
ROE-47.0%2022-01-01 → 2022-12-31Cons.Rate of return on equity (5-year summary)
ROE-53.9%2021-01-01 → 2021-12-31Cons.Rate of return on equity (5-year summary)
ROE18.3%2020-01-01 → 2020-12-31dCons.Rate of return on equity (5-year summary)
ROE13.3%2019-01-01 → 2019-12-31dCons.Rate of return on equity (5-year summary)
ROE8.4%2018-01-01 → 2018-12-31dCons.Rate of return on equity (5-year summary)
Employees210at 2022-12-31Cons.Number of employees
Employees264at 2021-12-31Cons.Number of employees
Employees274at 2020-12-31dCons.Number of employees
Employees233at 2019-12-31dCons.Number of employees
Employees229at 2018-12-31dCons.Number of employees
Revenue¥4.6bn2022-01-01 → 2022-12-31StandaloneNet sales
Revenue¥10.6bn2021-01-01 → 2021-12-31StandaloneNet sales
Revenue¥17.1bn2020-01-01 → 2020-12-31dStandaloneNet sales (5-year summary)
Revenue¥14.5bn2019-01-01 → 2019-12-31dStandaloneNet sales (5-year summary)
Revenue¥9.9bn2018-01-01 → 2018-12-31dStandaloneNet sales (5-year summary)
Operating income−¥3.0bn2022-01-01 → 2022-12-31StandaloneOperating income
Operating income−¥5.0bn2021-01-01 → 2021-12-31StandaloneOperating income
Ordinary income−¥3.3bn2022-01-01 → 2022-12-31StandaloneOrdinary income
Ordinary income−¥5.9bn2021-01-01 → 2021-12-31StandaloneOrdinary income
Ordinary income¥5.5bn2020-01-01 → 2020-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥3.5bn2019-01-01 → 2019-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥1.8bn2018-01-01 → 2018-12-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥4.9bn2022-01-01 → 2022-12-31StandaloneIncome before income taxes
Profit before tax−¥8.6bn2021-01-01 → 2021-12-31StandaloneIncome before income taxes
Net income−¥5.0bn2022-01-01 → 2022-12-31StandaloneProfit loss
Net income−¥9.3bn2021-01-01 → 2021-12-31StandaloneProfit loss
Net income¥3.9bn2020-01-01 → 2020-12-31dStandaloneNet income loss (5-year summary)
Net income¥2.4bn2019-01-01 → 2019-12-31dStandaloneNet income loss (5-year summary)
Net income¥1.3bn2018-01-01 → 2018-12-31dStandaloneNet income loss (5-year summary)
Total assets¥14.3bnat 2022-12-31StandaloneAssets
Total assets¥21.9bnat 2021-12-31StandaloneAssets
Total assets¥31.0bnat 2020-12-31dStandaloneTotal assets (5-year summary)
Total assets¥24.6bnat 2019-12-31dStandaloneTotal assets (5-year summary)
Total assets¥20.9bnat 2018-12-31dStandaloneTotal assets (5-year summary)
Total liabilities¥6.8bnat 2022-12-31StandaloneLiabilities
Total liabilities¥9.5bnat 2021-12-31StandaloneLiabilities
Net assets / equity¥7.5bnat 2022-12-31StandaloneNet assets
Net assets / equity¥12.4bnat 2021-12-31StandaloneNet assets
Net assets / equity¥22.2bnat 2020-12-31dStandaloneNet assets
Net assets / equity¥18.8bnat 2019-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥16.9bnat 2018-12-31dStandaloneNet assets (5-year summary)
Cash and deposits¥1.9bnat 2022-12-31StandaloneCash and deposits
Cash and deposits¥4.8bnat 2021-12-31StandaloneCash and deposits
EPS (basic)¥-113.642022-01-01 → 2022-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-213.032021-01-01 → 2021-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥89.572020-01-01 → 2020-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥55.312019-01-01 → 2019-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥31.092018-01-01 → 2018-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (diluted)¥89.212020-01-01 → 2020-12-31dStandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥55.092019-01-01 → 2019-12-31dStandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥31.052018-01-01 → 2018-12-31dStandaloneDiluted earnings per share (5-year summary)
Dividend per share¥252020-01-01 → 2020-12-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥502019-01-01 → 2019-12-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥352018-01-01 → 2018-12-31dStandaloneDividend paid per share (5-year summary)
Net assets per share¥171.91at 2022-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥284.83at 2021-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥512.14at 2020-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥436.46at 2019-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥392.92at 2018-12-31dStandaloneNet assets per share (5-year summary)
Equity ratio52.4%at 2022-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio56.6%at 2021-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio71.6%at 2020-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio76.1%at 2019-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio80.9%at 2018-12-31dStandaloneEquity to asset ratio (5-year summary)
ROE-49.8%2022-01-01 → 2022-12-31StandaloneRate of return on equity (5-year summary)
ROE-53.6%2021-01-01 → 2021-12-31StandaloneRate of return on equity (5-year summary)
ROE18.9%2020-01-01 → 2020-12-31dStandaloneRate of return on equity (5-year summary)
ROE13.2%2019-01-01 → 2019-12-31dStandaloneRate of return on equity (5-year summary)
ROE8.1%2018-01-01 → 2018-12-31dStandaloneRate of return on equity (5-year summary)
Shares issued44,136,900at 2022-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued44,136,900at 2021-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued44,001,900at 2020-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued14,567,300at 2019-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued14,344,100at 2018-12-31dStandaloneTotal number of issued shares (5-year summary)
Employees175at 2022-12-31StandaloneNumber of employees
Employees226at 2021-12-31StandaloneNumber of employees
Employees237at 2020-12-31dStandaloneNumber of employees
Employees211at 2019-12-31dStandaloneNumber of employees
Employees207at 2018-12-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 58
SegmentItemPeriodValue
Otherother segmentsrevenue2022-01-01 → 2022-12-31¥7m
Otherother segmentsrevenue external2022-01-01 → 2022-12-31¥7m
Otherother segmentssegment assetsat 2022-12-31¥10m
Otherother segmentssegment profit2022-01-01 → 2022-12-31−¥44m
Reconciling Itemsreconcilingcapex2022-01-01 → 2022-12-31¥20m
Reconciling Itemsreconcilingdepreciation2022-01-01 → 2022-12-31¥128m
Reconciling Itemsreconcilingsegment assetsat 2022-12-31¥5.4bn
Reconciling Itemsreconcilingsegment profit2022-01-01 → 2022-12-31−¥1.2bn
Infection Control Businessreportable segmentcapex2022-01-01 → 2022-12-31¥5m
Infection Control Businessreportable segmentdepreciation2022-01-01 → 2022-12-31¥60m
Infection Control Businessreportable segmentemployeesat 2022-12-3176 pure
Infection Control Businessreportable segmentrevenue2022-01-01 → 2022-12-31¥1.4bn
Infection Control Businessreportable segmentrevenue external2022-01-01 → 2022-12-31¥1.4bn
Infection Control Businessreportable segmentsegment assetsat 2022-12-31¥1.8bn
Infection Control Businessreportable segmentsegment profit2022-01-01 → 2022-12-31−¥2.2bn
Pharmaceuticals Businessreportable segmentcapex2022-01-01 → 2022-12-31¥17m
Pharmaceuticals Businessreportable segmentdepreciation2022-01-01 → 2022-12-31¥549m
Pharmaceuticals Businessreportable segmentemployeesat 2022-12-31109 pure
Pharmaceuticals Businessreportable segmentrevenue2022-01-01 → 2022-12-31¥3.6bn
Pharmaceuticals Businessreportable segmentrevenue external2022-01-01 → 2022-12-31¥3.6bn
Pharmaceuticals Businessreportable segmentsegment assetsat 2022-12-31¥7.8bn
Pharmaceuticals Businessreportable segmentsegment profit2022-01-01 → 2022-12-31¥297m
—segment totalemployeesat 2022-12-31185 pure
Total Of Reportable Segments And Otherssegment totalcapex2022-01-01 → 2022-12-31¥22m
Total Of Reportable Segments And Otherssegment totaldepreciation2022-01-01 → 2022-12-31¥609m
Total Of Reportable Segments And Otherssegment totalrevenue2022-01-01 → 2022-12-31¥5.0bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-01-01 → 2022-12-31¥5.0bn
Total Of Reportable Segments And Otherssegment totalsegment assetsat 2022-12-31¥9.6bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-01-01 → 2022-12-31−¥1.9bn
Otherother segmentsrevenue2021-01-01 → 2021-12-31¥6m
Otherother segmentsrevenue external2021-01-01 → 2021-12-31¥6m
Otherother segmentssegment assetsat 2021-12-31¥12m
Otherother segmentssegment profit2021-01-01 → 2021-12-31−¥68m
Reconciling Itemsreconcilingcapex2021-01-01 → 2021-12-31¥117m
Reconciling Itemsreconcilingdepreciation2021-01-01 → 2021-12-31¥109m
Reconciling Itemsreconcilingsegment assetsat 2021-12-31¥8.4bn
Reconciling Itemsreconcilingsegment profit2021-01-01 → 2021-12-31−¥1.4bn
Infection Control Businessreportable segmentcapex2021-01-01 → 2021-12-31¥309m
Infection Control Businessreportable segmentdepreciation2021-01-01 → 2021-12-31¥472m
Infection Control Businessreportable segmentrevenue2021-01-01 → 2021-12-31¥6.9bn
Infection Control Businessreportable segmentrevenue external2021-01-01 → 2021-12-31¥6.9bn
Infection Control Businessreportable segmentsegment assetsat 2021-12-31¥4.1bn
Infection Control Businessreportable segmentsegment profit2021-01-01 → 2021-12-31−¥4.9bn
Pharmaceuticals Businessreportable segmentcapex2021-01-01 → 2021-12-31¥656m
Pharmaceuticals Businessreportable segmentdepreciation2021-01-01 → 2021-12-31¥359m
Pharmaceuticals Businessreportable segmentrevenue2021-01-01 → 2021-12-31¥4.3bn
Pharmaceuticals Businessreportable segmentrevenue external2021-01-01 → 2021-12-31¥4.3bn
Pharmaceuticals Businessreportable segmentsegment assetsat 2021-12-31¥10.0bn
Pharmaceuticals Businessreportable segmentsegment profit2021-01-01 → 2021-12-31¥1.5bn
Total Of Reportable Segments And Otherssegment totalcapex2021-01-01 → 2021-12-31¥965m
Total Of Reportable Segments And Otherssegment totaldepreciation2021-01-01 → 2021-12-31¥831m
Total Of Reportable Segments And Otherssegment totalrevenue2021-01-01 → 2021-12-31¥11.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-01-01 → 2021-12-31¥11.3bn
Total Of Reportable Segments And Otherssegment totalsegment assetsat 2021-12-31¥14.2bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-01-01 → 2021-12-31−¥3.5bn
Infection Control Businessreportable segmentemployeesat 2022-12-3159 pure
Pharmaceuticals Businessreportable segmentemployeesat 2022-12-3191 pure
—segment totalemployeesat 2022-12-31150 pure

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,494
ItemContextValueUnit
Total changes of items during the periodCurrentYearDuration_ShareholdersEquityMember-4862000000JPY
Net assetsCurrentYearInstant_CapitalStockMember1201000000JPY
Net assetsCurrentYearInstant_CapitalSurplusMember1642000000JPY
Net assetsCurrentYearInstant_RetainedEarningsMember5239000000JPY
Net assetsCurrentYearInstant_TreasuryStockMember-348000000JPY
Net assetsCurrentYearInstant_ShareholdersEquityMember7734000000JPY
Net assetsPrior1YearInstant_ForeignCurrencyTranslationAdjustmentMember210000000JPY
Net assetsPrior1YearInstant_ValuationAndTranslationAdjustmentsMember210000000JPY
Net assetsPrior1YearInstant_SubscriptionRightsToSharesMember0JPY
Net assetsPrior1YearInstant12807000000JPY
Profit loss attributable to owners of parentCurrentYearDuration-4895000000JPY
Purchase of treasury stockCurrentYearDuration－JPY
Disposal of treasury stockCurrentYearDuration32000000JPY
Net changes of items other than shareholders equityCurrentYearDuration_ForeignCurrencyTranslationAdjustmentMember98000000JPY
Net changes of items other than shareholders equityCurrentYearDuration_ValuationAndTranslationAdjustmentsMember98000000JPY
Net changes of items other than shareholders equityCurrentYearDuration_SubscriptionRightsToSharesMember-0JPY
Net changes of items other than shareholders equityCurrentYearDuration98000000JPY
Total changes of items during the periodCurrentYearDuration_ForeignCurrencyTranslationAdjustmentMember98000000JPY
Total changes of items during the periodCurrentYearDuration_ValuationAndTranslationAdjustmentsMember98000000JPY
Total changes of items during the periodCurrentYearDuration_SubscriptionRightsToSharesMember-0JPY
Total changes of items during the periodCurrentYearDuration-4763000000JPY
Net assetsCurrentYearInstant_ForeignCurrencyTranslationAdjustmentMember309000000JPY
Net assetsCurrentYearInstant_ValuationAndTranslationAdjustmentsMember309000000JPY
Net assetsCurrentYearInstant_SubscriptionRightsToSharesMember－JPY
Net assetsCurrentYearInstant8044000000JPY
Income before income taxesPrior1YearDuration-8887000000JPY
Income before income taxesCurrentYearDuration-4869000000JPY
Depreciation and amortization ope cfPrior1YearDuration941000000JPY
Depreciation and amortization ope cfCurrentYearDuration737000000JPY
Impairment loss ope cfPrior1YearDuration2453000000JPY
Impairment loss ope cfCurrentYearDuration91000000JPY
Loss on retirement of noncurrent assets ope cfPrior1YearDuration3000000JPY
Loss on retirement of noncurrent assets ope cfCurrentYearDuration7000000JPY
Premium allowance of retirement ope cfPrior1YearDuration－JPY
Premium allowance of retirement ope cfCurrentYearDuration226000000JPY
Compensation expenses ope cfPrior1YearDuration359000000JPY
Compensation expenses ope cfCurrentYearDuration499000000JPY
Increase decrease in provision for sales returns ope cfPrior1YearDuration579000000JPY
Increase decrease in provision for sales returns ope cfCurrentYearDuration-699000000JPY
Increase decrease in refund liabilities ope cfPrior1YearDuration－JPY
Increase decrease in refund liabilities ope cfCurrentYearDuration94000000JPY
Increase decrease in provision for bonuses ope cfPrior1YearDuration-306000000JPY
Increase decrease in provision for bonuses ope cfCurrentYearDuration-125000000JPY
Increase decrease in provision for directors bonuses ope cfPrior1YearDuration-57000000JPY
Increase decrease in provision for directors bonuses ope cfCurrentYearDuration－JPY
Increase decrease in net defined benefit liability ope cfPrior1YearDuration63000000JPY
Increase decrease in net defined benefit liability ope cfCurrentYearDuration-146000000JPY
Increase decrease in provision for surcharge ope cfPrior1YearDuration－JPY
Increase decrease in provision for surcharge ope cfCurrentYearDuration607000000JPY
Interest and dividends income ope cfPrior1YearDuration-3000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 24 of 24 passed
balance sheet identityconsolidated 2021-12-31pass
balance sheet identityconsolidated 2022-12-31pass rounding
balance sheet identitynon_consolidated 2021-12-31pass
balance sheet identitynon_consolidated 2022-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2020-12-31pass
statement vs summary · net assetsconsolidated 2021-12-31pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net assetsnon_consolidated 2020-12-31pass
statement vs summary · net assetsnon_consolidated 2021-12-31pass
statement vs summary · net assetsnon_consolidated 2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-01-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-12-31pass
statement vs summary · operating cash flowconsolidated 2021-01-01/2021-12-31pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-01-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-01-01/2022-12-31pass
statement vs summary · revenuenon_consolidated 2021-01-01/2021-12-31pass
statement vs summary · revenuenon_consolidated 2022-01-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2021-12-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass
statement vs summary · total assetsnon_consolidated 2021-12-31pass
statement vs summary · total assetsnon_consolidated 2022-12-31pass